MYO — part of Money You are Owed

Free insurance appeal guide

How to Appeal a GLP-1 Insurance Denial

A step-by-step guide for a Wegovy denial, a Zepbound prior-authorization denial, or an Ozempic coverage dispute—including the Medicare-first check that may save you from filing the wrong appeal.

Start with the exact denial reason—not the drug name. “Wegovy denied by insurance” can mean a plan exclusion, missing prior authorization, unmet eligibility criteria, the wrong coverage route, or an excluded product or formulation. Each requires a different response.

Medicare first: check the GLP-1 Bridge before appealing

If you have Medicare Part D, first determine whether the denial should be handled through ordinary Part D coverage or through the temporary Medicare GLP-1 Bridge. The pilot runs from July 1, 2026 through December 31, 2027. It does not change the underlying Part D exclusion for weight-loss drugs. [CMS: Medicare GLP-1 Bridge; Medicare.gov]

The Bridge has a flat $50 monthly copay at any income. That payment does not count toward the Part D deductible or out-of-pocket maximum, and Extra Help does not apply. [Medicare fact sheet, Product No. 12234]

Products covered by the Bridge

Not covered through the Bridge: Zepbound single-dose pens or vials, Ozempic, and compounded GLP-1 products. [CMS; Medicare fact sheet 12234]

Bridge eligibility: every requirement must be met

  1. You have Part D coverage, but not through a private fee-for-service plan, cost plan, or PACE.
  2. You are not already receiving a GLP-1 drug through Part D.
  3. You do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver. Those conditions go through ordinary Part D coverage instead.
  4. You are at least 18 years old.
  5. You meet at least one of these clinical routes:
    • BMI of at least 35; or
    • BMI of at least 30 plus heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; or
    • BMI of at least 27 plus prediabetes or a prior heart attack, stroke, or peripheral artery disease.

[CMS: Medicare GLP-1 Bridge; Medicare fact sheet, Product No. 12234]

If your condition belongs in normal Part D, or the requested product is not a Bridge-covered formulation, identify that routing or product issue before writing an appeal.

Ordinary Part D deadlines and appeal order

A Part D coverage determination is due within 72 hours under the standard process or 24 hours when expedited. If the plan denies coverage, the first appeal is a redetermination by the plan. The next level is reconsideration by an independent review entity. [Medicare.gov]

Medicare beneficiaries can get free, one-to-one assistance through the State Health Insurance Assistance Program. Find the local program at SHIPhelp.org.

Step 1: find and quote the exact denial reason

Use the written denial notice as your map. Do not answer a vague summary such as “not covered” if the notice gives a more specific reason.

Make a one-page denial worksheet

  • Drug and formulation requested: for example, the tablet, injection, KwikPen, single-dose pen, or vial.
  • Exact denial language: copy it word for word.
  • Coverage route: commercial plan, ACA marketplace plan, Medicare Part D, or Medicare Advantage.
  • Decision being challenged: coverage denial or prior-authorization denial.
  • Appeal deadline: copy the date or filing window from the notice.
  • Facts that directly answer the denial: list only records or information relevant to the stated reason.

For an ACA-compliant non-grandfathered health plan, you generally have at least 180 days from the denial to file an internal appeal. That rule should not be assumed to apply identically to every type of coverage, so follow the instructions and deadline on your notice. [HealthCare.gov: internal appeals]

Step 2: put the denial into one of five buckets

Use the denial’s wording to choose the issue your appeal must answer.
Denial type What to check What the response should address
1. Coverage exclusion Does the notice say the drug or its use is excluded? Identify whether the dispute is truly an exclusion or whether another coverage route applies. For Medicare weight-loss coverage, check the temporary Bridge rather than assuming Part D’s underlying exclusion changed.
2. Prior authorization or missing support Does the notice say prior authorization was absent, incomplete, or denied? Answer the stated prior-authorization issue directly and organize the supporting information around the plan’s reason.
3. Eligibility or clinical criteria Does the notice say a required criterion was not met? Match each relevant documented fact to each criterion. For the Medicare Bridge, verify age, BMI route, qualifying conditions, excluded conditions, Part D status, and whether you already receive a GLP-1 through Part D.
4. Wrong program or indication route Should the request go through normal Part D rather than the Medicare Bridge, or vice versa? Correct the route. Under the Bridge rules, type 2 diabetes, moderate-to-severe sleep apnea, and fatty liver go through normal Part D.
5. Product or formulation mismatch Was the exact requested product eligible under the relevant program? Name the precise product. The Bridge covers Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen—not Ozempic, Zepbound single-dose pens or vials, or compounded products.

The GLP-1 Appeal Kit — $39

Five fill-in appeal letters, six insurer playbooks, prior-auth worksheet, escalation ladder. If this guide is the map, the kit is the done-for-you machine.

See the GLP-1 Appeal Kit

Step 3: build the internal appeal around the denial

  1. Lead with the decision you want reviewed.

    Name the drug and exact formulation, identify the denial, and state that you are requesting an internal appeal or—under Part D—a redetermination.

  2. Quote the denial reason.

    Copy the plan’s language. This keeps the appeal focused on the actual dispute.

  3. Respond point by point.

    If the notice lists several criteria, use the same order. Place the relevant fact or supporting record under each criterion rather than sending an undifferentiated stack of material.

  4. Correct routing and formulation errors explicitly.

    For Medicare, say whether the request belongs under ordinary Part D or the GLP-1 Bridge. If the issue is the formulation, name it precisely.

  5. Ask for a clear written decision.

    Retain a copy of the appeal and everything submitted with it. Follow the filing method and deadline in the denial notice.

A simple appeal-letter structure

Subject: Internal appeal of GLP-1 coverage denial

Request: “I am appealing the denial of [drug and exact formulation].”

Denial reason: Quote the notice exactly.

Response: Address each stated reason separately, using only relevant facts and supporting records.

Medicare routing, if applicable: State whether the request belongs through normal Part D or the Medicare GLP-1 Bridge, and why under the applicable eligibility and product rules.

Closing: Request review and a written decision. Include the identifying and submission information required by the notice.

Step 4: move to external review after an internal denial

External review is an independent review by an IRO after an internal denial. Under the federal process, the filing deadline is generally about four months. State procedures vary, so use the instructions and deadline that apply to your plan. [HealthCare.gov: external review]

For Part D, the named sequence is different: after the plan’s redetermination, the next appeal is reconsideration by an independent review entity. [Medicare.gov]

Do not treat “about four months” as a universal deadline. The federal external-review deadline and state processes are not identical. Read the denial instructions and preserve the earliest applicable deadline.

What the appeal statistics do—and do not—show

There is no single honest “GLP-1 appeal success rate” in the verified data. Two separate KFF analyses come closest, and they measure different things for different populations:

These figures cover different insurance markets and different points in the appeal process. They should not be blended into one predicted outcome for Wegovy, Zepbound, Ozempic, or any individual case. They do show the same pattern in both markets: very few denials are ever appealed, and a meaningful share of the ones that are get reversed.

If the appeal fails: verified self-pay prices

These are manufacturer self-pay options verified July 19, 2026. They are not the same as insurance coverage, and the terms differ by product.

Verified manufacturer self-pay pricing as of July 19, 2026.
Product Verified self-pay price Important condition
Wegovy through NovoCare $199 per month for the first two fills, then $349 per month Wegovy HD 7.2 mg is $399 per month.
Wegovy pill $149 per month Manufacturer self-pay price.
Zepbound through LillyDirect $299 for 2.5 mg; $399 for 5 mg; $449 for 7.5–15 mg Must refill within 45 days. Otherwise, 7.5 mg is $499 and higher doses can cost up to $699.

[Official manufacturer programs: NovoCare and LillyDirect, terms verified July 19, 2026]

Commercial savings cards are not Medicare or Medicaid options

For eligible people with commercial insurance, the Wegovy savings card can reduce the price to as little as $25 per month, with a maximum benefit of $100 per month. The Zepbound card can reduce the price to as little as $25 per fill of up to three months; that card expires December 31, 2026.

Manufacturer savings cards are for commercial insurance only and are never available for Medicare or Medicaid because of federal anti-kickback restrictions. Check the manufacturer’s current terms before relying on a card.

Be cautious with compounded GLP-1 claims

Compounded GLP-1 products have not been broadly legal since the FDA shortages were resolved in December 2024 and February 2025. Only a narrow, patient-specific 503A exception remains. In April 2026, the FDA proposed tightening the rules further. Compounded products are not covered by the Medicare GLP-1 Bridge. [FDA; CMS]

Frequently asked questions

What should I do if Wegovy was denied by insurance?

Read the written notice and copy the exact denial reason. Determine whether it is a coverage exclusion, prior-authorization issue, eligibility-criteria issue, wrong coverage route, or product/formulation mismatch. Build the appeal around that reason rather than sending a generic request.

How long do I have to appeal a GLP-1 denial?

ACA non-grandfathered plans allow at least 180 days from the denial to file an internal appeal. Other coverage types may use different procedures or deadlines, so follow your denial notice. A federal external-review deadline is generally about four months after the applicable internal denial, while state processes vary.

What happens after a Zepbound prior authorization is denied?

Use the denial notice to identify the unmet or missing requirement and file the applicable internal appeal. Quote the reason and answer each listed point. If you have Part D, the first appeal is a redetermination by the plan; the next level is reconsideration by an independent review entity.

Does the Medicare GLP-1 Bridge cover Ozempic?

No. The Bridge covers only Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen. It does not cover Ozempic, Zepbound single-dose pens or vials, or compounded GLP-1 products.

Is everyone with Medicare eligible for the $50 GLP-1 copay?

No. Every Bridge requirement must be met, including the Part D plan requirement, age requirement, applicable BMI and health-condition route, and the restrictions involving existing Part D GLP-1 coverage and certain diagnoses. The pilot runs only from July 1, 2026 through December 31, 2027.

Does the Medicare Bridge copay count toward my Part D deductible or out-of-pocket maximum?

No. The $50 monthly Bridge copay does not count toward either one. Extra Help does not apply to that copay.

Can I request an independent review?

External review by an independent review organization is available after an internal denial under the applicable process. The federal filing deadline is generally about four months, but state procedures vary. Under Part D, independent reconsideration follows the plan’s redetermination.

How often are insurance appeals successful?

There is no verified GLP-1-specific rate here. KFF found that 80.7% of appealed Medicare Advantage prior-authorization denials were overturned in 2024, but only 11.5% of denied requests were appealed at all. For ACA marketplace plans, fewer than 1% of denied claims were appealed. Those are different markets and decision types, so neither predicts an individual GLP-1 appeal.

Can someone help me with a Medicare GLP-1 appeal for free?

Yes. The State Health Insurance Assistance Program provides free help to people with Medicare. Find the local program at SHIPhelp.org.

Primary sources used

The GLP-1 Appeal Kit — $39

Five fill-in appeal letters, six insurer playbooks, prior-auth worksheet, escalation ladder. If this guide is the map, the kit is the done-for-you machine.

Get the GLP-1 Appeal Kit